Search Results

New turnkey research facility will provide AAALAC-accredited flexible vivarium space for Massachusetts biopharmaceutical hub Charles River Laboratories International, Inc. has announced the opening of a new Charles River Accelerator and Development Lab facility on Chestnut Street in Somerville, Massachusetts, an emerging life sciences hub.

Charles River Laboratories International, Inc. today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its Virtual Control Groups (VCG) initiative with Sanofi.

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.7% from $1.03 billion in the first quarter of 2023.

Charles River Laboratories International, Inc. announced the publication of its 2023 Corporate Citizenship Report, which includes progress and results from 2022 and 2023.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced it has reached 100 percent renewable electricity across all of its global sites as of the first quarter of 2024, significantly ahead of the original target date.

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4th , at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 5th , at 10:00 a.m. ET.